Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock

Does systolic blood pressure (SBP) modify the survival benefit of microaxial flow pump therapy in ST-segment elevation myocardial infarction–related cardiogenic shock?In this post hoc analysis of the DanGer Shock randomized clinical trial including 351 patients, SBP at randomization significantly modified the survival benefit of microaxial flow pump therapy, with benefit most pronounced in patients with the lowest SBPs. Adverse events occurred independently of SBP at randomization.Early SBP may help identify patients most likely to derive a net benefit from microaxial flow pump treatment in infarct-related cardiogenic shock.

Corresponding Author: Astrid Duus Mikkelsen, MD, Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark (astrid.duus.mikkelsen@reigonh.dk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.